Logo

Fennec Pharmaceuticals’ Pedmarqsi (sodium thiosulfate) Receives EC’s Marketing Authorization for Cisplatin-Induced Ototoxicity

Share this
Fennec

Fennec Pharmaceuticals’ Pedmarqsi (sodium thiosulfate) Receives EC’s Marketing Authorization for Cisplatin-Induced Ototoxicity

Shots:

  • The EC has granted the marketing authorization for Pedmarqsi to prevent ototoxicity (hearing loss) induced by cisplatin CT in patients aged 1mos. to <18yrs. with localized, non-metastatic solid tumors
  • The decision was based on 2 P-III trials (SIOPEL 6) & (COG Protocol ACCL0431) evaluating Pedmarqsi + cisplatin-based regimen vs cisplatin-based regimens alone. The results showed that the hearing loss incidence rate was lower in the Pedmarqsi + cisplatin arm vs cisplatin alone (28.6% vs 56.4%) in (COG ACCLO431) & 35.1% vs 67.3% in (SIOPEL6) studies
  • The marketing authorization is valid for all 27 EU member states, Iceland, Norway, and Liechtenstein. Pedmarqsi is currently marketed as Pedmark in the US

Ref: Globenewswire | Image: Fennec

Related News:- Fennec Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Pedmarqsi for Cisplatin-Induced Ototoxicity in Pediatric Patients

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions